Monitoring cellular accumulation of 3′-deoxy-3′-fluorothymidine (FLT) and its monophosphate metabolite (FLT-MP) by LC-MS/MS as a measure of cell proliferation in vitro

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 28, 2011, Pages 2963-2970

  Li, Wenlin ^a   Araya, Marcela ^b   Elliott, Mark ^a   Kang, Xiaolin ^a   Gerk, Phillip M ^b   Halquist, Matthew S ^b   Karnes, H Thomas ^b   Zhang, Cathy ^a   O'Brien, Peter J ^a  

^a PFIZER INC   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

3 Deoxy 3 fluorothymidine (FLT); 3 Deoxy 3 fluorothymidine monophosphate (FLT MP); Cell proliferation assay; Detection of tumor growth; LC MS MS; Microplate format

Indexed keywords

ACCURATE MEASUREMENT; ALTERNATIVE METHODS; ANIMAL MODELS OF CANCER; ATP GENERATION; CELL COUNTING; CELL CYCLE; CELL NUMBER; CONTROL PRECISION; CULTURE MEDIUM; DIRECT ASSESSMENT; DRUG DEVELOPMENT; DRUG SCREENING; IN-VITRO; INHIBITOR DRUGS; INTERNAL STANDARDS; LC-MS/MS; LIMIT OF QUANTIFICATIONS; LINEARLY PROPORTIONAL; LNCAP CELLS; MICROPLATES; MONOPHOSPHATES; PEAK AREA RATIOS; PROLIFERATING CELLS; PROSTATE CANCER CELLS; THYMIDINE KINASE; TUMOR TISSUES;

ASSAYS; CELL PROLIFERATION; CELLS; DISEASES; GROWTH KINETICS; METABOLISM; METABOLITES; QUALITY CONTROL; TUMORS;

CELL CULTURE;

3' FLUOROTHYMIDINE; DRUG METABOLITE; THYMIDINE KINASE 1;

ARTICLE; CANCER CELL; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TANDEM MASS SPECTROMETRY;

CELL LINE, TUMOR; CELL PROLIFERATION; CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIDEOXYNUCLEOSIDES; ENZYME ASSAYS; HUMANS; MODELS, BIOLOGICAL; TANDEM MASS SPECTROMETRY; THYMIDINE KINASE;

ANIMALIA;

EID: 80053574801     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2011.08.024     Document Type: Article

References (32)

1. NCGC Assay Guidance 2009, National Institutes of Health Chemical Genomics Center, Bethesda, MD. N.I.o.H.C.G. Center (Ed.).
2. Hu V.W., Black G.E., Torres-Duarte A., Abramson F.P. FASEB J. 2002, 16:1456.
3. Davison P., Liu S., Karasek M. Cell Tissue Kinet. 1979, 12:605.
4. Masterson J.C., O'Dea S. Anticancer Drugs 2007, 18:1053.
5. Erikstein B.S., Hagland H.R., Nikolaisen J., Kulawiec M., Singh K.K., Gjertsen B.T., Tronstad K.J. J. Cell. Biochem. 2010, 111:574.
6. Bodycote J., Wolff S. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:4749.
7. Olivieri G., Bodycote J., Wolff S. Science 1984, 223:594.
8. Sims J.T., Plattner R. Cancer Chemother. Pharmacol. 2009, 64:629.
9. Monteiro-Riviere N.A., Inman A.O., Zhang L.W. Toxicol. Appl. Pharmacol. 2009, 234:222.
10. Wang P., Henning S.M., Heber D. PLoS One 2010, 5:e10202.
11. de Bono J.S., Ashworth A. Nature 2010, 467:543.
12. Salskov A., Tammisetti V.S., Grierson J., Vesselle H. Semin. Nucl. Med. 2007, 37:429.
13. Munch-Petersen B., Cloos L., Jensen H.K., Tyrsted G. Adv. Enzyme Regul. 1995, 35:69.
14. Rasey J.S., Grierson J.R., Wiens L.W., Kolb P.D., Schwartz J.L. J. Nucl. Med. 2002, 43:1210.
15. Eriksson S., Kierdaszuk B., Munch-Petersen B., Oberg B., Johansson N.G. Biochem. Biophys. Res. Commun. 1991, 176:586.
16. Dittmann H., Jusufoska A., Dohmen B.M., Smyczek-Gargya B., Fersis N., Pritzkow M., Kehlbach R., Vonthein R., Machulla H.J., Bares R. Nucl. Med. Biol. 2009, 36:163.
17. Budavari S., O'Neil M.J., Smith A., Heckelman P.E., Kinneary J.F. The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals 1996, Merck & Co., Inc., Whitehouse Station, NJ.
18. Fowler J.S., Ding Y.S., Volkow N.D. Semin. Nucl. Med. 2003, 33:14.
19. Kraus S., Gioeli D., Vomastek T., Gordon V., Weber M.J. Cancer Res. 2006, 66:11047.
20. Knowles J.R. Annu. Rev. Biochem. 1980, 49:877.
21. FDA Guidances (Drugs) 2001.
22. Horiatis D., Wang Q., Pinski J. Cancer Lett. 2004, 210:119.
23. Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand E.A., Murphy G.P. Cancer Res. 1983, 43:1809.
24. Ryu C.K., Kang H.Y., Lee S.K., Nam K.A., Hong C.Y., Ko W.G., Lee B.H. Bioorg. Med. Chem. Lett. 2000, 10:461.
25. Lee E.C., Frolov A., Li R., Ayala G., Greenberg N.M. Cancer Res. 2006, 66:4996.
26. Panvichian R., Orth K., Pilat M.J., Day M.L., Day K.C., Yee C., Kamradt J.M., Pienta K.J. Urology 1999, 54:746.
27. Sekhon B.K., Roubin R.H., Tan A., Chan W.K., Sze D.M. Assay Drug Dev. Technol. 2008, 6:711.
28. de Fries R., Mitsuhashi M. J. Clin. Lab. Anal. 1995, 9:89.
29. Mueller H., Kassack M.U., Wiese M. J. Biomol. Screen. 2004, 9:506.
30. Wittstock M., Rehfeldt C., Mix E., Zettl U.K. Anal. Biochem. 2001, 292:166.
31. Murigande C., Regenass S., Wirz D., Daniels A.U., Tyndall A. Immunol. Invest. 2009, 38:67.
32. Houghton R., Horro Pita C., Ward I., Macarthur R. Bioanalysis 2009, 1:1365.